Isofol Medical AB (publ)

Kvartalsrapporter

Visar 1 grupper

  1. Kvartalsrapport Q1 2026

    ENSV
    →

    Financial Position

    • Cash and cash equivalents amounted to kSEK 110,741 (82,108) as of March 31, 2026.
    • The exercise of warrants of series TO1 resulted in proceeds of approximately mSEK 18.9 before issue costs (mSEK 17.6…

    Öppna rapport